

# **Pulmonary Function Tests**

Mohammad Babai M.D

Occupational Medicine Specialist

[babai@behban.ir](mailto:babai@behban.ir)

# Pulmonary Function Tests

## n Pulmonary Function Tests:

n **Spirometry**

n Peak-Flow metry

n Bronchoprovocation Tests

n Body Box Plethysmography


n Nitrogen Washout Test

n DLco

# **SPIROMETRY**

## **Physiology**

- n Tidal Volume**
- n Inspiratory Reserve Volume**
- n Expiratory Reserve Volume**
- n Residual Volume**
- n Vital Capacity**
- n Total Lung Capacity**



# **SPIROMETRY**

## **Instrument**

- n Volume measuring Spirometers**

- n Flow measuring Spirometers**

  - n Hot wire cooling**

  - n IR scattering**

# **SPIROMETRY**

## **The FVC Maneuver**

- n Maximal inspiration and then rapidly, forcefully and completely exhale.**
- n Sitting or Standing.**
- n Nose clip.**
- n No hesitation in start of test.**
- n Patient Instruction is necessary.**

Expiration

PEF Flow (L/sec)

FEF<sub>25%</sub>

FEF<sub>50%</sub>

FEF<sub>75%</sub>

FEV<sub>1/2</sub>

FEV<sub>1</sub>

FVC

FEV<sub>3</sub>

Vol [l]

2

4

6


Inspiration

FIF<sub>25%</sub>

FIF<sub>75%</sub>

FIF<sub>50%</sub>

10



# **SPIROMETRY**

## **Spirometric Parameters**

- n Forced Vital Capacity (FVC)**
- n Forced expiratory Volume in 1st second (FEV1)**
- n FEV1/FVC**
- n Peak expiratory flow rate (PEFR)**
- n Mean expiratory flow during the middle half of FVC (FEF25-75)**



# **SPIROMETRY**

## **Acceptability of Spirogram**

- n At least 3 forced expiratory curves that are free from:**
  - n Interruptions due to coughing, glottis closure or...**
  - n Hesitant or false start.**
  - n Inconsistent effort.**
  - n Early termination.**
  - n Excessive variability (Two largest FVC or FEV1 should not vary by more than 5%) .**

# SPIROMETRY

## Acceptability Criteria

- n Maximal inspiration at start
- n Maximal expiratory effort with no hesitation or false start (VEXT or Back Extrapolated volume  $< 5\%$  of FVC if FVC is more than 3 liters or  $< 150\text{ml}$  if FVC less than 3 liters)
- n No cough or discontinuity of effort in the first second
- n No obstruction of airflow by mouthpiece, tongue, teeth or glottis
- n Satisfactory end of effort (Plateau on volume-time curve with  $< 40\text{ ml}$  exhaled over the last 2 seconds or usually at least 6 seconds)
- n No leak (e.g., from nose, lips, mouthpiece ,...)

# SPIROMETRY

## Reproducibility Criteria

- n Largest and second largest FVC within 5% or 100 ml
- n Largest and second largest FEV1 within 5% or 100 ml

# SPIROMETRY

## Spirometric Tests Interpretation

- n Selecting Predicted Values:**

Age, Gender, Race, Height,

- n Setting Lower Limit of Normal (LLN):**

- n 80% of predicted values.**

- n 95<sup>th</sup> percentile method.**

- n 95% confidence interval[Predicted value-(1.645\*SEE)]**

# SPIROMETRY

## Selecting Predicted Values:

- n Almost 100 published paper about “Reference Value” in the world
- n Two published papers in international journals from Iran:
  - n Boskabadi ( 2002)
  - n Golshan ( 2003)
- 3-4 published paper about reference value in Iranian Journal:
  - Kashan
  - Kordestan
  - Yazd
  - sari

# SPIROMETRY

## Selecting Predicted Values:

**n ERS/ECSS predicted values for men:**

**n FVC = 5.76 H -0.026A-4.34 ( SEE=0.61)**


**n FEV1 = 4.30H-0.029A-2.49 (SEE= 0.51)**

**n ERS/ECSS predicted values for women:**

**n FVC = 4.43 H -0.026A-2.89 ( SEE=0.43)**

**n FEV1 = 3.95H-0.025A-2.60 (SEE= 0.38)**

**Start  
Here**



# SPIROMETRY

## Spirometric Tests Interpretation

### n **Severity of Obstruction:**

n **Mild:**  $FEV1 \geq 70\%$

n **Moderate:**  $60\% \leq FEV1 < 70\%$

n **Moderately Severe:**  $50\% \leq FEV1 < 60\%$

n **Severe:**  $34\% \leq FEV1 < 50\%$

n **Very Severe:**  $FEV1 < 34\%$



# SPIROMETRY

## Spirometric Tests Interpretation

### n **Severity of Restriction\*:**

n **Mild:**  $70\% \leq \text{FVC} < \text{LLN}$

n **Moderate:**  $60\% \leq \text{FVC} < 70\%$

n **Moderately Severe:**  $50\% \leq \text{FVC} < 60\%$

n **Severe:**  $34\% \leq \text{FVC} < 50\%$

n **Very Severe:**  $\text{FVC} < 34\%$

\*When TLC is not available.

LLN = Lower Limit of Normal.

# SPIROMETRY

## Reporting

- n A testing session may consist of three to eight acceptable efforts
- n Failure to meet acceptability and reproducibility criteria should be noted. The largest FEV1 and the Largest FVC from all acceptable maneuvers should be reported.

# SPIROMETRY

## Common Mistakes

- n Erroneous measurement of patient's height
- n Errors arising from selected reference value
- n Early Termination
- n Poor Effort ( Weak Push ) ( Inadequate Force )
- n Small inspiration
- n Poor Start
- n Poor reproducibility

# Measurement of Real Height

- n Use of arm span
- n Indication:
  - n Kyphoscoliosis
  - n Paralytic individuals
  - n Lower extremities amputation
- n Method:
- n Correct measurement of arm span
  - n Men:  $\text{real length} = \text{arm span} / 1.03$
  - n Women:  $\text{real length} = \text{arm span} / 1.01$

# **SPIROMETRY**

## **Analysis of trends: cross sectional vs. longitudinal**

- n When PFT is measured at regular intervals, the resulting data must be looked as trend of changes besides.**
- n After age 35 to 40 the annual decline of FEV1 & FVC in adults is about 25 to 30 ml.**
- n There is an acceleration in the rate of decline with age.**

# **SPIROMETRY**

## **Analysis of trends: Confounding factors**

- n PFTs done by different instruments**
- n PFTs done by different technicians**
- n PFTs interpreted using different predicted values**
- n PFTs done at different times of day( up to 5% variation)**
- n PFTs done when the subject was not healthy enough**
- n Learning effect**

# **SPIROMETRY**

## **Analysis of trends**

- n ATS : A greater than 15% change from year to year has to be considered significant.**
- n Zenz : A greater than 10% change from year to year has to be considered significant, 15% change is clinically significant.**
- n When comparing PFTs in longer intervals, be sure to adjust aging effect( 30 ml/yr )**

# **SPIROMETRY**

## **Bronchodilator studies**

- n It is used to assess reversibility of airway obstruction**
- n Test to test & day to day variability**
- n An acute response to B.D correlates with clinical response to B.D or corticosteroid therapy in asthma & COPD**



# **SPIROMETRY**

## **Bronchodilator studies**

- n Most laboratories use  $\beta$ -agonists**
- n The use of a large volume spacer device is recommended**
- n Commercially available preparations of  $\beta$ -agonists use an alcohol carrier, which may irritate the airways (**Paradoxical bronchospasm**)**

# SPIROMETRY

## Bronchodilator studies

- n The lack of an acute B.D response does not rule out the presence of airway hyperresponsiveness
- n The lack of an acute B.D response does not preclude a beneficial clinical response to B.D therapy
- n Significant response may be determined on the basis of change in F-V curve shape, Subjective judgment, the magnitude of change in FEV1(12% with an absolute value >200ml

# **SPIROMETRY**

## **Preshift & Postshift testing**

- n It can demonstrate a significant physiologic change that may be related to workplace.**
- n Quality control is of paramount importance in performing comparative measurements.**
- n PFT indices are Max in early morning and Min in early afternoon with an 5% variation.**
- n A 10% decline in PFT indices during working shift is regarded significant.**
- n Delayed response to workplace exposures may not be detected by this method.**

# **SPIROMETRY**

## **Peak Flow measurement**

- n Follow daily trends in patients.**
- n Results are expressed as a percentage of the mean value for the 15-day period.**
- n A greater than 20% change in peak flow is usually considered significant.**
- n It is useful in detecting a relationship to occupational exposures when coupled with symptoms, use of medications and daily activities.**

# **SPIROMETRY**

## **Peak Flow measurement**

- n It is effort dependent.**
- n The patient should be well trained to be consistent.**
- n The patient is not blinded to results.**
- n Peak flow has greater within-person variability than FEV1 and may underestimate the degree of impairment in severe obstructive patients.**
- n Some patients with severe airway obstruction can have normal peak flows.**
- n Peak flow can be reduced for reasons other than airway obstruction.**

# **SPIROMETRY**

## **Peak Flow measurement**

- n The devices are not indestructible!**
- n The devices` accuracy may be impaired because of wetness or accumulated dust.**
- n There is no inexpensive calibration method available.**
- n Routine periodic replacement of Peakflowmeters is recommended.**

# **SPIROMETRY**

## **Measurement of absolute lung volumes**

- n Gas dilution techniques:**
  - n Helium dilution**
  - n Nitrogen washout**
- n Body box plethysmography**
- n Radiographic techniques**

# SPIROMETRY

## Gas transfer studies

- n Diffusing capacity measurement evaluates the absorption and excretion gas between the alveoli and the pulmonary capillaries.
- n DLCO is a function of *Surface area of alveolar membrane* , *efficiency of alveolar membrane* and *pulmonary capillary bed*.



# **SPIROMETRY**

## **Gas transfer studies**

- n Confounding factors are:**
  - n Variations in hemoglobin**
  - n Variations in carboxyhemoglobin**
  - n Altitude**
  - n Body position**

# **SPIROMETRY**

## **Gas transfer studies**

- n No consensus regarding indications for measurement of DLCO.**
- n Valuable screening test and a sensitive indicator of occupational-related interstitial disease.**
- n Possible indications are: restrictive disorders, obstructive disorders, cardiovascular disorders, other causes of gas exchange impairment and disability evaluation.**

# **SPIROMETRY**

## **Gas transfer studies**

- n DLCO is abnormal in restrictive disorders. (useful for diagnosis & long term follow up)**
- n DLCO is reduced in emphysema & cystic fibrosis.**
- n DLCO is reduced in thromboembolism, fat embolism, pulmonary hypertension & pulmonary edema.**
- n DLCO is increased in obesity, asthma, polycythemia, pulmonary hemorrhage, exercise & increased pulmonary capillary bed (e.g. left to right intracardiac shunt) .**

# **SPIROMETRY**

## **Bronchoprovocation Tests**

### **n Bronchial Challenge:**

**n Histamine**

**n Metacholine**

**n Cold Air**

**n Exercise**

**n PC20: The concentration of metacholine causing a 20% drop in FEV1**

**n Normal subjects have a  $PC20 \geq 8$**

# **SPIROMETRY**

## **Bronchoprovocation Tests**

- n Screening Occupational Asthma:**
  - n In Preplacement Exams for places with known occupational sensitizers.**
  - n The presence of hyperresponsiveness should not be used to exclude worker, repeating test serially may lead to Asthma Dx.**

# **SPIROMETRY**

## **Bronchoprovocation Tests**

- n Diagnosing Occupational Asthma:**
  - n In subjects with symptoms & FEV1/FVC > LLN**

